Murphy resigns from MaxCyte
Plus AbbVie’s Severino becomes CEO-partner at Flagship, and updates from Ikena, Fusion, Nimbus and more
CFO Amanda Murphy will resign from MaxCyte Inc. (LSE:MXCT; NASDAQ:MXCT) on April 15 to pursue other interests. SVP and Chief Accounting Officer Ron Holtz, who was the company’s CFO from 2005 until 2020, will become interim CFO. The cell engineering company said that it expects the revenue for 1Q22 to be at least $11 million, compared with $6.5 million in 1Q21. Consolidated financial statements will be released in May.
Flagship Pioneering named Michael Severino as CEO-partner and CEO of an undisclosed portfolio company. Severino was most recently vice chairman and president at AbbVie Inc. (NYSE:ABBV). He previously was SVP of global development and corporate CMO at Amgen Inc. (NASDAQ:AMGN), and a senior director at Merck & Co. Inc. (NYSE:MRK). Flagship added Margo Georgiadis and Michelle Werner as CEO-Partners earlier this month...